Taylor KM - Search Results

1

Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells.

Hiscox S, Jordan NJ, Smith C, James M, Morgan L, Taylor KM, Green TP, Nicholson RI. Hiscox S, et al. Among authors: taylor km. Breast Cancer Res Treat. 2009 May;115(1):57-67. doi: 10.1007/s10549-008-0058-6. Epub 2008 May 21. Breast Cancer Res Treat. 2009. PMID: 18493848

2

Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation.

Hiscox S, Jiang WG, Obermeier K, Taylor K, Morgan L, Burmi R, Barrow D, Nicholson RI. Hiscox S, et al. Int J Cancer. 2006 Jan 15;118(2):290-301. doi: 10.1002/ijc.21355. Int J Cancer. 2006. PMID: 16080193

3

ZIP7-mediated intracellular zinc transport contributes to aberrant growth factor signaling in antihormone-resistant breast cancer Cells.

Taylor KM, Vichova P, Jordan N, Hiscox S, Hendley R, Nicholson RI. Taylor KM, et al. Endocrinology. 2008 Oct;149(10):4912-20. doi: 10.1210/en.2008-0351. Epub 2008 Jun 26. Endocrinology. 2008. PMID: 18583420

4

Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance.

Thomas NB, Hutcheson IR, Campbell L, Gee J, Taylor KM, Nicholson RI, Gumbleton M. Thomas NB, et al. Among authors: taylor km. Breast Cancer Res Treat. 2010 Feb;119(3):575-91. doi: 10.1007/s10549-009-0355-8. Epub 2009 Mar 15. Breast Cancer Res Treat. 2010. PMID: 19288272

5

Development of strategies for the use of anti-growth factor treatments.

Jones HE, Gee JM, Taylor KM, Barrow D, Williams HD, Rubini M, Nicholson RI. Jones HE, et al. Among authors: taylor km. Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S173-82. doi: 10.1677/erc.1.01004. Endocr Relat Cancer. 2005. PMID: 16113094 Review.

6

Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.

Nicholson RI, Hutcheson IR, Jones HE, Hiscox SE, Giles M, Taylor KM, Gee JM. Nicholson RI, et al. Among authors: taylor km. Rev Endocr Metab Disord. 2007 Sep;8(3):241-53. doi: 10.1007/s11154-007-9033-5. Rev Endocr Metab Disord. 2007. PMID: 17486454 Review.

7

The LZT proteins; the LIV-1 subfamily of zinc transporters.

Taylor KM, Nicholson RI. Taylor KM, et al. Biochim Biophys Acta. 2003 Apr 1;1611(1-2):16-30. doi: 10.1016/s0005-2736(03)00048-8. Biochim Biophys Acta. 2003. PMID: 12659941 Free article. Review.

8

Structure-function analysis of LIV-1, the breast cancer-associated protein that belongs to a new subfamily of zinc transporters.

Taylor KM, Morgan HE, Johnson A, Hadley LJ, Nicholson RI. Taylor KM, et al. Biochem J. 2003 Oct 1;375(Pt 1):51-9. doi: 10.1042/BJ20030478. Biochem J. 2003. PMID: 12839489 Free PMC article.

9

Zinc transporter LIV-1: a link between cellular development and cancer progression.

Taylor KM, Hiscox S, Nicholson RI. Taylor KM, et al. Trends Endocrinol Metab. 2004 Dec;15(10):461-3. doi: 10.1016/j.tem.2004.10.003. Trends Endocrinol Metab. 2004. PMID: 15541644

10

The emerging role of the LIV-1 subfamily of zinc transporters in breast cancer.

Taylor KM, Morgan HE, Smart K, Zahari NM, Pumford S, Ellis IO, Robertson JF, Nicholson RI. Taylor KM, et al. Mol Med. 2007 Jul-Aug;13(7-8):396-406. doi: 10.2119/2007-00040.Taylor. Mol Med. 2007. PMID: 17673939 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

686 results

Search Page

Filters